Geriatrics Department, Rouen University Hospital, Rouen, France.
J Nutr Health Aging. 2013 Feb;17(2):196-8. doi: 10.1007/s12603-012-0375-7.
Merkel cell carcinoma (MMC) is a rare primary neuroendocrine skin tumor associated with a poor prognosis. MMC is histologically similar to small cell lung carcinoma. The incidence of MCC is increasing with a median age of discovery of approximately 70 years old. Treatment of MCC, which usually occurs in sun-exposed skin, includes surgery with reconstruction associated with radiotherapy and/or chemotherapy for advanced stages including widespread metastases. We report two cases of Merkel cell carcinoma in 76 and 84 year old patients and describe the natural history of this cancer and management in geriatric patients. Merkel cell carcinoma (MCC) is a rare cancer with high malignant potential that mainly affects people over the age of 65. It must be diagnosed early to improve the prognosis. The survival rate at 5 years for local or regional invasion is 65%. The median survival for metastasized stages is 10 months. The therapeutic regimen recommended for the treatment of MCC is influenced by the geriatric status of patients, and a multidisciplinary oncogeriatric approach could be of interest.
默克尔细胞癌（MCC）是一种罕见的与预后不良相关的原发性神经内分泌皮肤肿瘤。MCC 在组织学上类似于小细胞肺癌。MCC 的发病率正在增加，发现时的中位年龄约为 70 岁。MCC 通常发生在阳光暴露的皮肤，治疗包括手术和重建，对于晚期包括广泛转移的情况，还需要联合放疗和/或化疗。我们报告了两名 76 岁和 84 岁的 Merkel 细胞癌患者的病例，并描述了这种癌症的自然病史以及在老年患者中的治疗管理。默克尔细胞癌（MCC）是一种恶性程度高、罕见的癌症，主要发生在 65 岁以上的人群中。为了改善预后，必须早期诊断。局部或区域侵袭的 5 年生存率为 65%。转移性阶段的中位生存期为 10 个月。推荐的 MCC 治疗方案受患者的老年状况影响，多学科肿瘤老年学方法可能具有重要意义。
